Upadacitinib Beats Placebo in Phase 3 Trials for Severe Alopecia Areata

Alopecia areata (AA) is an autoimmune disease in which T lymphocytes attack hair follicles, producing patchy or complete scalp and body hair loss. For most of the twentieth century, treatment was limited to intralesional corticosteroids, topical minoxidil, and contact sensitizers — none of them effective for severe or total hair loss. The discovery that JAK-STAT signaling drives the immune attack on follicles changed the picture dramatically, and two oral JAK inhibitors — baricitinib and ritlecitinib — already carry FDA approval for severe AA. Now, two parallel Phase 3 replicate RCTs published in JAMA Dermatology add upadacitinib to that list.[1]

The trials enrolled adults and adolescents (aged 12 and older) with severe alopecia areata, defined as at least 50% scalp hair loss on the Severity of Alopecia Tool (SALT) score. Participants were randomized to upadacitinib 15 mg daily, upadacitinib 30 mg daily, or placebo for 36 weeks. The primary endpoint was the proportion of patients achieving a SALT score of 20 or less — meaning at least 80% scalp coverage — at week 36.[1]

Both dose groups significantly outperformed placebo. In the combined analysis, approximately 35–40% of participants receiving upadacitinib 30 mg achieved SALT ≤20 versus roughly 5–8% on placebo — a difference of about 30 percentage points. The 15 mg dose produced somewhat lower but still significant response rates. Adolescents responded comparably to adults. Eyebrow and eyelash regrowth followed scalp regrowth. The safety profile was consistent with upadacitinib's established profile in rheumatoid arthritis and atopic dermatitis: infection rates were higher in the treatment arms, with upper respiratory infections being the most common adverse event. No new cardiovascular or malignancy signals emerged at 36 weeks.[1]

Clinical Context

The treatment landscape for severe alopecia areata was transformed by the baricitinib approval in June 2022 — the first FDA-approved systemic therapy for severe AA. The BRAVE-AA1 and BRAVE-AA2 trials (NEJM 2022) randomized 1,200 patients with severe AA (SALT score ≥50) to baricitinib 2 mg, baricitinib 4 mg, or placebo; at 36 weeks, 35% of patients on the 4 mg dose achieved SALT ≤20 (≥80% scalp hair coverage) versus only 4% on placebo.[2] Ritlecitinib, a JAK3/TEC family inhibitor with a more targeted kinase profile, was approved in June 2023 (ALLEGRO trial); it demonstrated comparable SALT ≤20 response rates with a potentially more selective immune footprint. JAK inhibitors are now guideline-recommended for severe AA in adults who have not responded to intralesional corticosteroids.

Upadacitinib is a selective JAK1 inhibitor (IC50 for JAK1 approximately 43-fold lower than JAK2) already approved for rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, Crohn's disease, and ulcerative colitis — making it one of the broadest-indication JAK inhibitors on the market. Its approval for severe AA is not unexpected given the class's established mechanism, but the specific profile of upadacitinib — once-daily oral dosing, potency, and the extensive safety dataset from its other indications — adds a meaningful treatment option. For AA specifically, the relevance of JAK1 selectivity is debated: AA pathophysiology involves IFN-γ (JAK1/JAK2 signaling) and IL-15 (JAK1/JAK3), and the clinical response rates across JAK inhibitors with different selectivity profiles have been broadly similar.[3]

Why It Matters Clinically

The JAK inhibitor revolution in alopecia areata is one of the more striking examples of targeted immunotherapy transforming a disease that previously had no effective systemic treatment. The mechanism is clear: JAK-STAT signaling (particularly JAK1 and JAK3) is required for IFN-γ-driven T cell attack on hair follicles. Blocking JAK activity removes the inflammatory signal and allows follicle recovery. Upadacitinib's selective JAK1 inhibition provides a somewhat different safety and efficacy profile than the earlier agents, and head-to-head trials comparing JAK inhibitors directly are now needed to guide sequencing decisions.[2]

Limitations

Trial duration was 36 weeks — adequate to assess initial response but insufficient to determine durability. Alopecia areata is a relapsing disease, and whether hair regrowth is maintained after treatment discontinuation remains incompletely characterized for all JAK inhibitors in this class. Long-term safety monitoring for malignancy and cardiovascular risk is required.